ATLANTA--(BUSINESS WIRE)--NeurOp, Inc. today announced that Bristol-Myers Squibb (NYSE: BMY) has agreed to fund an additional year of research for NeurOp’s proprietary small molecules for the treatment of major depression and neuropathic pain.
ATLANTA--(BUSINESS WIRE)--NeurOp, Inc. today announced that Bristol-Myers Squibb (NYSE: BMY) has agreed to fund an additional year of research for NeurOp’s proprietary small molecules for the treatment of major depression and neuropathic pain.
